GL Sciences Inc. carries a market capitalization of 28.31B, placing it among publicly traded companies globally. Its enterprise value stands at 34.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 28.31B |
| Enterprise Value | 34.06B |
GL Sciences Inc. currently has 10.26M shares outstanding.
| Shares Outstanding | 10.26M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
GL Sciences Inc. trades at a trailing price-to-earnings ratio of 8.23. The price-to-sales ratio is 0.76, and the price-to-book ratio stands at 0.94.
| PE Ratio | 8.23 |
| PS Ratio | 0.76 |
| PB Ratio | 0.94 |
| P/TBV Ratio | 0.71 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, GL Sciences Inc. trades at an EV/EBITDA multiple of 5.96 and an EV/FCF ratio of 924.73. The EV/Sales ratio of 0.92 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.96 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.92 |
| EV / EBITDA | 5.96 |
| EV / EBIT | 5.96 |
| EV / FCF | 924.73 |
GL Sciences Inc. maintains a current ratio of 3.14, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.68, indicating elevated leverage, while an interest coverage ratio of 108.44 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.14 |
| Quick Ratio | 0.70 |
| Debt / Equity | 16.68 |
| Debt / EBITDA | 1.17 |
| Interest Coverage | 108.44 |
GL Sciences Inc. posts a return on equity of 11.97 and a return on invested capital of 8.72.
| Return on Equity (ROE) | 11.97 |
| Return on Assets (ROA) | 6.44 |
| Return on Invested Capital (ROIC) | 8.72 |
| Return on Capital Employed (ROCE) | 6.08 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.00 |
Over the trailing twelve months, GL Sciences Inc. has paid 1.88B in income taxes, reflecting an effective tax rate of 30.10.
| Income Tax | 1.88B |
| Effective Tax Rate | 30.10 |
GL Sciences Inc.'s stock has gained approximately 24.22332% over the past 52 weeks. The 50-day moving average sits at 2,647.54, while the 200-day moving average is 2,766.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | 24.22332% |
| 50-Day Moving Average | 2,647.54 |
| 200-Day Moving Average | 2,766.05 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, GL Sciences Inc. generated 37.15B in revenue and converted that into 3.43B in net income, yielding earnings per share of 425.52. EBITDA reached 5.71B, while operating income came in at 5.71B.
| Revenue | 37.15B |
| Gross Profit | 13.49B |
| Operating Income | 5.71B |
| Pretax Income | 6.25B |
| Net Income | 3.43B |
| EBITDA | 5.71B |
| EBIT | 5.71B |
| Earnings Per Share (EPS) | 425.52 |
GL Sciences Inc. holds 7.45B in cash and equivalents against 6.71B in total debt, resulting in a net debt position of -743.24M. Total book value stands at 30.05B, with working capital of 22.74B providing operational flexibility.
| Cash & Cash Equivalents | 7.45B |
| Total Debt | 6.71B |
| Net Debt | -743.24M |
| Equity (Book Value) | 30.05B |
| Book Value Per Share | 2,928.64 |
| Working Capital | 22.74B |
GL Sciences Inc. operates with a gross margin of 36.31, reflecting its pricing power and cost economics. The operating margin of 15.38 and net profit margin of 9.24 provide insight into operational efficiency.
| Gross Margin | 36.31 |
| Operating Margin | 15.38 |
| Pretax Margin | 16.81 |
| Profit Margin | 9.24 |
| EBITDA Margin | 15.38 |
GL Sciences Inc.'s most recent stock split took place on June 26, 2015 with a 1:2 split ratio.
| Last Split Date | 6/26/2015 |
| Split Ratio | 1:2 |
GL Sciences Inc. posts an Altman Z-Score of 3.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.35 |